Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL28458407 | 0.94 | ALDH1A1 (0.46) | ALDH1A1TSHRFFAR3LMNAHSD17B10 | |
| Ether SCHEMBL613941 | 0.89 | — | — | |
| Ether SCHEMBL9339223 | 0.89 | ALDH1A1 (0.46) | ALDH1A1TSHRFFAR3LMNAHSD17B10 | |
| Pyruvate SCHEMBL27965997 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TSHRFFAR3LMNAHSD17B10 | |
| Tetrylammonium SCHEMBL27877454 | 0.86 | TSHR (0.42) | ALDH1A1TSHRFFAR3LMNAHSD17B10 | |
| Ether SCHEMBL9225910 | 0.86 | ALDH1A1 (0.43) | ALDH1A1TSHRFFAR3LMNAHSD17B10 | |
| Ether SCHEMBL29058438 | 0.86 | ALDH1A1 (0.43) | ALDH1A1TSHRFFAR3LMNAHSD17B10 | |
| Ether SCHEMBL20338904 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3LMNAHSD17B10 | |
| Ether SCHEMBL28393262 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3LMNAHSD17B10 | |
| Ether SCHEMBL115545 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082542-A | Phosphorus-free corrosion and scale inhibitor and preparation method and application thereof | 嘉兴沃特泰科环保科技股份有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-113929464-A | CNT/graphene covalent modified high-thermal-conductivity carbide ceramic and preparation method thereof | 航天特种材料及工艺技术研究所 | 2022-01-14 | — | — | CN | claimed |
| CN-106478938-B | PEG modifier and its preparation of a kind of cucoline and its derivative | 成都一平医药科技发展有限公司 | 2019-05-28 | — | — | CN | claimed |
| CN-106478938-A | The PEG trim of a kind of sinomenine and its derivant and its preparation | 成都平医药科技发展有限公司 | 2017-03-08 | — | — | CN | claimed |
| CN-116082542-A | Phosphorus-free corrosion and scale inhibitor and preparation method and application thereof | 嘉兴沃特泰科环保科技股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116082542-A | Phosphorus-free corrosion and scale inhibitor and preparation method and application thereof | 嘉兴沃特泰科环保科技股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-113929464-B | CNT/graphene covalent modified high-thermal-conductivity carbide ceramic and preparation method thereof | 航天特种材料及工艺技术研究所 | 2022-10-25 | — | — | CN | disclosed |
| CN-113929464-A | CNT/graphene covalent modified high-thermal-conductivity carbide ceramic and preparation method thereof | 航天特种材料及工艺技术研究所 | 2022-01-14 | — | — | CN | disclosed |
| CN-109956941-B | Simple preparation method of abamectin | 新发药业有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-106478938-B | PEG modifier and its preparation of a kind of cucoline and its derivative | 成都一平医药科技发展有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-105330576-B | The phosphate analogs of aryl bicyclic sphingol 1 | 比奥根MA公司 | 2018-04-10 | — | — | CN | disclosed |
| CN-107429069-A | Resin combination, laminate structure and its manufacture method | 住友电气工业株式会社 | 2017-12-01 | — | — | CN | disclosed |
| CN-106478938-A | The PEG trim of a kind of sinomenine and its derivant and its preparation | 成都平医药科技发展有限公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-105330576-A | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC INC | 2016-02-17 | — | — | CN | disclosed |
| CN-102548409-B | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-104447321-A | Alcohol ether ester carboxylate (AEEC) and synthetic process thereof | JIANGSU WAN QI BIOTECHNOLOGY CO LTD | 2015-03-25 | — | — | CN | disclosed |
| CN-102548409-A | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC INC | 2012-07-04 | — | — | CN | disclosed |
| EP-1513835-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-08-16 | — | — | EP | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | ALDH1A1 445/4885TSHR 192/4885FFAR3 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.